Recruiting first, then most recently updated. Showing 37 of 37.
- Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With InfluenzaRecruitingNCT07357051Phase 3
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPDRecruitingNCT07351734Phase 2
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- A Phase 3 Trial of JKN2401 Injection in COPDNot yet recruitingNCT07330310Phase 3
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy VolunteersRecruitingNCT07207291Phase 1
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee ArthroplastyRecruitingNCT06963320Phase 2
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux EsophagitisRecruitingNCT06850480Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- A Study to Evaluate the Efficacy and Safety of LZM012RecruitingNCT06110676Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- A Phase 2 Trial of JKN24011 in COPDCompletedNCT07440524Phase 2
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )CompletedNCT07746479Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPDCompletedNCT07450482Phase 2
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- DBM-1152A Inhalation Solution in Chinese Healthy SubjectsCompletedNCT07447141Phase 1
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- DBM-1152A Inhalation Solution in Healthy VolunteersCompletedNCT07439419Phase 1
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- JKN2306 in Healthy Subjects: Single Ascending Dose and Food Effect StudyCompletedNCT07412938Phase 1
Sponsor listed in the registry: Joincare Pharmaceutical Group Industry Co., Ltd
- A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer BleedingCompletedNCT05841394Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)CompletedNCT05050474Phase 1
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster StudyCompletedNCT05096832Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase IIIStatus unknownNCT05096845Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5Status unknownNCT05585567Early Phase 1
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351Status unknownNCT05583357Early Phase 1
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein VaccineStatus unknownNCT05238649Phase 2
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- The Immunogenicity and Safety of V-01-351/V-01D Bivalence VaccineStatus unknownNCT05273528Phase 2
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and ImmunogencityStatus unknownNCT05239832Phase 2
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster ImmunizationStatus unknownNCT05125874Not applicable
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- LZM009 to Treat Patients With Advanced Solid TumorsCompletedNCT03286296Phase 1
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in USCompletedNCT04026321Phase 1
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .Status unknownNCT03456609Not applicable
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .Status unknownNCT03455205Not applicable
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese PatientsCompletedNCT03362281Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese PatientsCompletedNCT03362268Phase 2
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter PyloriCompletedNCT02873065Phase 4
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese PatientsCompletedNCT02860624Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Ilaprazole for the Treatment of Duodenal Ulcer in Chinese PatientsCompletedNCT02847455Phase 2/3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori InfectionCompletedNCT02835560Phase 4
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSHStatus unknownNCT02307994Phase 4
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese PatientsStatus unknownNCT01107938Phase 2
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)CompletedNCT00953381Phase 2
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.
- Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)CompletedNCT00952978Phase 3
Sponsor listed in the registry: Livzon Pharmaceutical Group Inc. · First submitted after Livzon Pharmaceutical Group Inc. became part of Joincare Pharmaceutical Group Industry Co., Ltd.